DVA & Humana Expand Value-Based Care for Kidney Disease Patients

DaVita DVA recently announced a new value-based care agreement with Humana to provide comprehensive, coordinated care to more than 10,000 Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. The program, which began on July 1, expands on the companies’ existing collaboration in end-stage kidney disease to earlier stages of CKD, where timely intervention may help delay disease progression and reduce hospitalizations.

Per management, kidney care is undergoing a therapeutic revolution, with upstream interventions helping to reshape patient outcomes. Through the partnership with Humana, DaVita is deploying advanced care that treats the whole patient, helps preserve kidney function and serves as a central hub for managing comorbid conditions that affect kidney health.

DVA Stock Trend Following the News

Following the announcement, shares of DVA inched up 0.7% at yesterday’s close. Year to date, the stock has surged 56.5% compared with the industry’s 23.6% growth and the S&P 500’s 11.4% rise.

The expanded partnership with Humana is a positive development for DaVita as it strengthens the company’s presence in value-based kidney care and broadens its role beyond end-stage kidney disease management. Serving more than 10,000 additional patients could support greater engagement in earlier-stage CKD while creating opportunities to improve clinical outcomes and reduce costly hospitalizations. Over time, successful execution of the model could reinforce DaVita’s value-based care capabilities and support further partnerships with health plans.

DVA currently has a market capitalization of $11.26 billion.

Image Source: Zacks Investment Research

More on the News

The program focuses on CKD patients at stages 3B–5, a critical point when kidney function may decline rapidly but the condition can remain underdiagnosed or undertreated. Through DaVita Integrated Kidney Care (DaVita IKC), the company provides coordinated, whole-person care that addresses the close links between kidney, cardiovascular and metabolic health, with the goal of reducing care gaps and preventing avoidable hospitalizations.

The program builds on DaVita’s network of approximately 3,000 value-based nephrologist partners. Patients receive support from an interdisciplinary care team designed to address clinical and nonclinical barriers, including nutrition, transportation and mental health needs. The value-based model also provides education and advance care planning for patients who progress toward kidney failure, including guidance on home dialysis and kidney transplantation.

By bringing these services together, DaVita aims to stabilize kidney function, slow disease progression and create a smoother transition between stages of care. The expanded partnership reflects the growing focus on value-based, preventive care and DaVita’s strategy of intervening earlier to better manage complex kidney disease and improve outcomes.

Industry Prospects Favoring the Market

Going by data provided by Global Market Insights, the U.S. dialysis services market is predicted to be valued at $37.7 billion in 2026 and is expected to witness a CAGR of 3.5% through 2035.

Factors such as the rising number of end-stage renal disease patients, increasing incidence of diabetes leading to kidney disorders, favorable reimbursement scenario available for dialysis treatment and expansion of dialysis centers across the United States are expected to support market growth.

Other News

Recently, DaVita exited the second quarter of 2026, wherein both earnings and revenues surpassed the estimates. Revenue per treatment was up year over year, but down sequentially. Solid revenues from both Dialysis patient service and Other sources, higher U.S. dialysis treatments per day and an uptick in normalized non-acquired treatment were encouraging. Management highlighted plans to expand hemodialysis across its network once an adequate supply of newly approved dialyzers is secured. Compatible with existing machines, the technology can broaden patient access without significant capital investment and may improve clinical outcomes, with mortality-related economic benefits expected from 2028.

DaVita Inc. Price

DaVita Inc. price | DaVita Inc. Quote

DVA’s Zacks Rank & Key Picks

Currently, DVA carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST.

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research